Biogen Idec agrees to pay $32.5 million upfront for preclinical CNS antibody portfolio
This article was originally published in Scrip
Executive Summary
Biogen Idec has agreed to pay $32.5 million up front and up to $395 million in milestone payments for three preclinical immunotherapy programmes from its partner Neurimmune.
You may also be interested in...
Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates
The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.